Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy

Author:

Grieve Stacy12ORCID,Puvvada Nagaprasad34,Phinyomark Angkoon25,Russell Kevin6,Murugesan Alli16,Zed Elizabeth7,Hassan Ansar28,Legare Jean-Francois28,C Kienesberger Petra269,Pulinilkunnil Thomas269,Reiman Tony1267,Scheme Erik256,R Brunt Keith236ORCID

Affiliation:

1. Department of Biology, University of New Brunswick, Saint John, New Brunswick, Canada

2. IMPART investigator team, Canada

3. Department of Pharmacology, Dalhousie University, Saint John, New Brunswick, Canada

4. Department of Chemistry, Indrashil University, Gujarat, India

5. Institute of Biomedical Engineering, University of New Brunswick, Fredericton, New Brunswick, Canada

6. Faculty of Medicine, Dalhousie University, Saint John, New Brunswick, Canada

7. Department of Oncology, Saint John Regional Hospital, Saint John, New Brunswick, Canada

8. Department of Cardiac Surgery, Saint John Regional Hospital, Saint John, New Brunswick, Canada

9. Department of Biochemistry & Molecular Biology, Dalhousie University, Saint John, New Brunswick, Canada

Abstract

Aim: Monitoring minimal residual disease remains a challenge to the effective medical management of hematological malignancies; yet surface-enhanced Raman spectroscopy (SERS) has emerged as a potential clinical tool to do so. Materials & methods: We developed a cell-free, label-free SERS approach using gold nanoparticles (nanoSERS) to classify hematological malignancies referenced against two control cohorts: healthy and noncancer cardiovascular disease. A predictive model was built using machine-learning algorithms to incorporate disease burden scores for patients under standard treatment upon. Results: Linear- and quadratic-discriminant analysis distinguished three cohorts with 69.8 and 71.4% accuracies, respectively. A predictive nanoSERS model correlated (MSE = 1.6) with established clinical parameters. Conclusion: This study offers a proof-of-concept for the noninvasive monitoring of disease progression, highlighting the potential to incorporate nanoSERS into translational medicine.

Funder

New Brunswick Innovation Foundation

Canadian Cancer Society

Dalhousie Medicine Research Foundation

Fondation de la recherche en santé du Nouveau-Brunswick

Canadian Institutes of Health Research

National Science and Engineering Research Council

Leukemia Lymphoma Society of Canada

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3